Lipodystrophic Nonalcoholic Fatty Liver Disease Induced by Immune Checkpoint Blockade
Thomas Eigentler, Diana Lomberg, Jürgen Machann, Norbert Stefan
Abstract
Letters16 June 2020Lipodystrophic Nonalcoholic Fatty Liver Disease Induced by Immune Checkpoint BlockadeThomas Eigentler, MD, Diana Lomberg, MD, Jürgen Machann, PhD, and Norbert Stefan, MDThomas Eigentler, MDUniversity Hospital of Tübingen, Tübingen, Germany (T.E., D.L.), Diana Lomberg, MDUniversity Hospital of Tübingen, Tübingen, Germany (T.E., D.L.), Jürgen Machann, PhDInstitute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, Tübingen, Germany (J.M.), and Norbert Stefan, MDInstitute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich and University Hospital of Tübingen, Tübingen, Germany and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts (N.S.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/L19-0635 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Programmed cell death protein 1 (PD-1) promotes apoptosis of antigen-specific T cells in lymph nodes, and cancer takes advantage of this mechanism to prevent the immune system from attacking cancer cells. Giving patients checkpoint inhibitors, which are antibodies directed against PD-1 and similar proteins, has revolutionized the treatment of cancer, especially malignant melanoma. However, this therapy may cause immune-related adverse events that usually can be controlled but also may be severe. These adverse events commonly affect the skin, gastrointestinal tract, lungs, and endocrine system (especially the thyroid, adrenal, and pituitary glands) and, less often, the musculoskeletal, renal, nervous, hematologic, ...References1. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158-168. [PMID: 29320654] doi:10.1056/NEJMra1703481 CrossrefMedlineGoogle Scholar2. Ahmadian M, Suh JM, Hah N, et al. PPARγ signaling and metabolism: the good, the bad and the future. Nat Med. 2013;19:557-66. [PMID: 23652116] doi:10.1038/nm.3159 CrossrefMedlineGoogle Scholar3. Stefan N, Schick F, Häring HU. Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans. Cell Metab. 2017;26:292-300. [PMID: 28768170] doi:10.1016/j.cmet.2017.07.008 CrossrefMedlineGoogle Scholar4. Hooper AJ, Adams LA, Burnett JR. Genetic determinants of hepatic steatosis in man. J Lipid Res. 2011;52:593-617. [PMID: 21245030] doi:10.1194/jlr.R008896 CrossrefMedlineGoogle Scholar5. Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6:e821-e830. [PMID: 31611038] doi:10.1016/S2352-3018(19)30338-8 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University Hospital of Tübingen, Tübingen, Germany (T.E., D.L.)Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, Tübingen, Germany (J.M.)Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich and University Hospital of Tübingen, Tübingen, Germany and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts (N.S.)Financial Support: Dr. Stefan is supported by a Heisenberg Professorship from the German Research Foundation.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L19-0635.This article was published at Annals.org on 3 March 2020. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe role of hepatokines in NAFLDHepatoprotective effect of botanical drug formula on high-fat diet-induced non-alcoholic fatty liver disease by inhibiting lipogenesis and promoting anti-oxidationPrädiabetes – eine Krankheit?PPARγ Gene as a Possible Link between Acquired and Congenital Lipodystrophy and its Modulation by Dietary Fatty AcidsDiabetes und FettleberDiabetes and Fatty LiverDiabetes und FettleberIst Prädiabetes behandlungsbedürftig?A global view of the interplay between non-alcoholic fatty liver disease and diabetesPD-1 inhibitor causes pathological injury to multiple organs in a Lewis lung cancer mouse modelMolecular and Cellular Bases of Lipodystrophy SyndromesUnderstanding the genetic architecture of the metabolically unhealthy normal weight and metabolically healthy obese phenotypes in a Korean populationUnravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to BedsideCOVID-19 infection and body weight: A deleterious liaison in a J-curve relationshipNon-alcoholic fatty liver disease in polycystic ovarian syndrome in Indian womenDiabetes und FettleberThe Troubling Link Between Non-alcoholic Fatty Liver Disease (NAFLD) and Extrahepatic Cancers (EHC)Carbohydrates deteriorate fatty liver by activating the inflammatory responseKommentarDiabetes und FettleberCOVID-19 severity in obese patients: Potential mechanisms and molecular targets for clinical interventionCharacterization of hyperglycemia in patients receiving immune checkpoint inhibitors: Beyond autoimmune insulin-dependent diabetesExcess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD)Emerging prevalence of fatty liver disease in HIVSystematic Review and Meta-analysis of Circulating Fetuin-A Levels in Nonalcoholic Fatty Liver DiseaseNivolumabDiabetes und FettleberKommentarMetabolically Healthy and Unhealthy Normal Weight and ObesityFettleber und Diabetes: PathomechanismenNeue arzneitherapeutische Optionen bei nichtalkoholischer FettlebererkrankungCauses, consequences, and treatment of metabolically unhealthy fat distribution 16 June 2020Volume 172, Issue 12Page: 836-837KeywordsAdipose tissueAdverse eventsBiopsyBone marrowFatsInflammationLipodystrophyLiverMastocytosisNon-alcoholic fatty liver disease ePublished: 3 March 2020 Issue Published: 16 June 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...